W911SR23F0049↗
Battelle Memorial Institute received this contract from W6QK Acc-Apg, Department of the Army: $22.31M obligated so far for national defense r&d services; department of defense - military; basic research. It runs to 2028-02-16.
Key facts · data as of Oct 28, 2026
- Recipient
- Battelle Memorial Institute
- Awarding agency
- Department of the Army (Department of Defense)
- Contracting office
- W6QK Acc-Apg (W911SR)
- Obligated to date
- $22.31M
- Potential value
- $49.50M
- Ends
- 2028-02-16
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 28, 2026.
Cite this page: SpendQuery, Award W911SR23F0049, data as of Oct 28, 2026, https://spendquery.com/award?id=CONT_AWD_W911SR23F0049_9700_GS00Q14OADU402_4732
Battelle Memorial Institute: all federal awards · Department of Defense: spending · W6QK Acc-Apg: what it buys · The follow-on: recompete brief
PERFORMANCE OF STUDIES IN SUPPORT OF THE CET-RAIDIR PROGRAM.
Obligated to date$22.31M29 actions
Current value$49.50Mwith options exercised
Period2023-02-17 → 2028-02-16current end date
Passed on$5.63Mto 7 subcontractors
Up for re-bid: ends 2028-02-16. Recompete brief →
What it is
- Product or service
- National Defense R&D Services; Department of Defense - Military; Basic Research (PSC AC11)
- Industry
- Research and Development in the Physical, Engineering, and Life Sciences (Except Biotechnology) (NAICS 541712)
- Contracting office
- W6QK Acc-Apg (W911SR)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Cost plus fixed fee
- How it was bought
- Multiple-award IDIQ · under OASIS (GS00Q14OADU402)
- Where the work is
- Franklin, OH · district OH-03
Obligations by fiscal year
FY2023$3.47M
FY2024$5.00M
FY2025$12.60M
FY2026$1.24M
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
8 subawards totaling $5.63M (25.2% of what was obligated), as Battelle Memorial Institute reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| The Geneva Foundation | $2.58M | 1 | WA | 2025-01-14 | 2025-01-14 |
| Envigo Global Services Inc | $1.32M | 2 | PA | 2024-07-01 | 2024-11-27 |
| Trustees of Boston University | $1.06M | 1 | MA | 2024-03-08 | 2024-03-08 |
| Inotiv, Inc | $499.1K | 1 | PA | 2025-04-01 | 2025-04-01 |
| Biomodal Inc | $72.6K | 1 | CA | 2026-04-14 | 2026-04-14 |
| Roche Holding Ag | $57.9K | 1 | IN | 2026-04-30 | 2026-04-30 |
| Iit Research Institute | $32.0K | 1 | IL | 2024-08-14 | 2024-08-14 |
The largest single subawards
| Date | To | Amount | For |
|---|---|---|---|
| 2025-01-14 | The Geneva Foundation | $2.58M | EVALUATION OF ERVEBO |
| 2024-03-08 | Trustees of Boston University | $1.06M | DETERMINE THE EFFICACY OF OBELDESIVIR, THE ORAL REMDESIVIR |
| 2024-07-01 | Envigo Global Services Inc | $675.9K | ANIMALS, REQUIRED TESTING, SURGERY AND TRANSPORT |
| 2024-11-27 | Envigo Global Services Inc | $647.2K | ***PURCHASE OF NHP'S**** |
| 2025-04-01 | Envigo Global Services Inc | $499.1K | ANIMALS AND TESTING SERVICES. |
| 2026-04-14 | Biomodal Inc | $72.6K | PURCHASE OF DUET MULTIOMICS AND UDI |
| 2026-04-30 | Roche Diagnostics Corporation | $57.9K | 0000933946 |
| 2024-08-14 | Iit Research Institute | $32.0K | SAMPLE ANALYSIS |
Every action
29 actions since 2023-02-17. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-06-10 | P00028 | Administrative change | -$321.0K | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. |
| 2026-01-30 | P00027 | Supplemental agreement (work within scope) | $1.13M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. |
| 2026-01-21 | P00026 | Funding only | -$252.1K | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. |
| 2025-12-16 | P00025 | Funding only | $676.9K | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002, CLIN 0003, AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. |
| 2025-09-26 | P00024 | Funding only | $957.5K | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002 AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. |
| 2025-09-18 | P00023 | Supplemental agreement (work within scope) | $333.9K | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002 AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. |
| 2025-08-15 | P00022 | Funding only | $2.26M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002 AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. |
| 2025-07-30 | P00021 | Funding only | $3.26M | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING TO CLIN 0002 AND CLIN 0006 UNDER DELIVERY ORDER W911SR-23-F-0049. SEE SUMMARY OF CHANGES. |
| 2025-04-28 | P00020 | Funding only | $2.88M | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2025-03-14 | P00019 | Funding only | $20.0K | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2025-02-04 | P00018 | Supplemental agreement (work within scope) | $1.50M | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-12-11 | P00017 | Supplemental agreement (work within scope) | $631.6K | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-11-06 | P00016 | Funding only | $754.4K | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-09-03 | P00015 | Supplemental agreement (work within scope) | $1.07M | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-06-06 | P00014 | Administrative change | $0 | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-06-04 | P00013 | Administrative change | $0 | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-05-23 | P00012 | Supplemental agreement (work within scope) | $1.77M | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-04-05 | P00011 | Supplemental agreement (work within scope) | $236.8K | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-02-27 | P00010 | Supplemental agreement (work within scope) | $946.1K | TO DESIGN AND CONDUCT NONCLINICAL RESEARCH STUDIES, DEVELOP SUPPORTING ASSAYS AND REAGENTS, INTERPRET AND REPORT STUDY RESULTS AND ANALYSIS, AND EVALUATE ADVANCED DEVELOPMENT CANDIDATES FOR REPURPOSED MEDICAL PRODUCTS AND VACCINE DEVELOPMENT. |
| 2024-01-11 | P00009 | Funding only | $201.2K | NON-CLNICAL STUDIES |
| 2024-01-09 | P00008 | Funding only | $517.1K | NON-CLNICAL STUDIES |
| 2023-11-16 | P00007 | Funding only | $262.9K | COUNTERING EMERGING THREATS RAPID ACQUISITION AND INVESTIGATION OF DRUGS FOR REPURPOSING DEVELOPMENT SUPPORT STUDIES. |
| 2023-08-29 | P00006 | Supplemental agreement (work within scope) | $282.2K | NON-CLNICAL STUDIES |
| 2023-08-15 | P00005 | Supplemental agreement (work within scope) | $460.9K | NON-CLNICAL STUDIES |
| 2023-08-07 | P00004 | Supplemental agreement (work within scope) | $554.1K | NON-CLNICAL STUDIES |
| 2023-07-20 | P00003 | Supplemental agreement (work within scope) | $188.7K | NON-CLNICAL STUDIES |
| 2023-06-07 | P00002 | Funding only | $61.9K | NON-CLINICAL STUDIES |
| 2023-05-24 | P00001 | Supplemental agreement (work within scope) | $376.4K | NON-CLNICAL STUDIES |
| 2023-02-17 | 0 | $1.54M | PERFORMANCE OF STUDIES IN SUPPORT OF THE CET-RAIDIR PROGRAM. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-28). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗